Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Long-term viremia and fecal shedding in pups after modified-live canine parvovirus vaccination

Nicola Decaro a,∗, Giuseppe Crescenzo a, Costantina Desario a, Alessandra Cavalli a, Michele Losurdo a, Maria Loredana Colaianni b, c, Gianpiero Ventrella a, Stefania Rizzi c, d, Stefano Aulicino c, Maria Stella Lucente a, Canio Buonavoglia a

a Department of Veterinary Medicine, University of Bari, Valenzano, Bari, Italy
b Istituto Zooprofilattico Sperimentale di Puglia e Basilicata, Foggia, Italy
c Ospedale Veterinario Pingry, Bari, Italy
d Cocker House – Allevamento “dei Machich”, Mola di Bari, Italy

Article history:
Received 20 March 2014
Received in revised form 7 April 2014
Accepted 17 April 2014
Available online 30 April 2014

Keywords:
Canine parvovirus
Vaccination
Virus shedding
Viremia

1. Introduction

Along with canine coronavirus [1,2], canine parvovirus (CPV) is the main cause of acute hemorrhagic enteritis in young dogs, which may display very severe clinical signs such as leukopenia, fever, inappetence, hemorrhagic diarrhea, dehydration and death [3]. Currently, three different antigenic variants are known, namely CPV-2a, CPV-2b and CPV-2c, which are variously distributed worldwide [4–8]. The original type CPV-2, albeit no longer circulating in the field, is still contained in most CPV vaccines, whereas few commercially-available vaccines are prepared with CPV-2b [3]. Although CPV-2c is becoming the predominant strain in several countries [4–8], to date there are no licensed vaccines that contain the newest variant. Both CPV-2 and CPV-2b vaccinal strains cause viremia and are shed with the feces of immunized dogs, as also shown by their detection in specimens from dogs displaying acute gastroenteritis shortly after vaccination, alone or in addition to CPV field strains or other pathogens [9]. However, nothing is known about the real duration and extent of viremia and shedding of vaccinal CPVs.

The aim of the present paper is to report the results of virological investigations carried out on pups routinely undergoing CPV vaccination in order to assess the vaccine virus viremia and shedding with the feces.

2. Materials and methods

2.1. Vaccines

Two commercial modified live virus (MLV) vaccines were used in the study, Nobivac® PUPPY CP (Intervet Italia S.r.l, Milan, Italy) and Duramune® DAPNI + LC (Zoetis Italia S.r.l., Rome, Italy), containing >107 and 104.7–106.5 tissue culture infectious doses of CPV-2 strain 154 and CPV-2b strain SAH, respectively.
2.2. Vaccination protocol

A total of 26 pups belonging to two different breeding kennels were recruited in the study with the written consent of the breeders. The dogs, 16 males and 10 females, consisted of 13 American cocker spaniels and 13 Labrador retrievers that were randomly divided into two vaccine groups (on the basis of the vaccine administered) in order to include both breeds and genders in each group. At the age of 6 weeks, all pups were bled to collect sera that were submitted to hemagglutination inhibition (HI) in order to predict the most appropriate age of vaccination on the basis of their maternally-derived antibody (MDA) titers [10]. When MDA titers were below the levels interfering with CPV vaccination (<1:20), pups were administered subcutaneously one dose of CPV-2 or CPV-2b vaccine according to the vaccine group.

2.3. Sample collection

Vaccinated animals were monitored for a period of 28 days post-vaccination (dpv) in order to evaluate vaccinal strain viremia, shedding and seroconversion.

For virological investigations, EDTA–blood samples and fecal specimens were collected from vaccinated pups at dpv 3, 7, 10, 14, 17, 21, 24 and 28 by means of jugular venipuncture and anal swabs, respectively. Serological testing was carried out on serum samples taken once a week from each dog.

2.4. Virological investigations

2.4.1. In-clinic test

The in-clinic test was carried out with the commercial kit WITNESS Parvo test (Symbiotics Corporation, Pfizer), as previously described [11]. The fecal material was collected on the test kit swab following the manufacturer’s instructions. The extraction buffer/conjugate was dispensed into the sample tube via the kit swab. Then, the sample swab was inserted into the tube containing the liquid and vortexed. The extracted fecal material/conjugate liquid was transferred to the WITNESS Parvo device using the swab pipette for the test kit as per manufacturer’s instructions.

2.4.2. Hemagglutination (HA)

Two-fold dilutions of the supernatant of each fecal homogenate were made in PBS (pH 7.2) starting from a 1:2 dilution [12]. Tests were carried out in 96-well V-plates (50 μL of sample dilution per well); equal amounts of a suspension containing 0.8% pig erythrocytes and 1% fetal calf serum (FCS) were added to each dilution. Results were read after 4 h at +4 °C and expressed as the reciprocal of the highest sample dilutions able to produce HA.

2.4.3. Real-time PCR assays for CPV detection, quantification and characterization

Specimens were homogenized (10%, w/v) in Dulbecco’s modified Eagle’s medium (DMEM) and subsequently clarified by centrifuging at 2500 × g for 10 min. Viral DNA was extracted from the supernatants of fecal homogenates by boiling for 10 min and chilling on ice. To reduce residual inhibitors of DNA polymerase activity to ineffective concentrations, the DNA extract was diluted 1:10 in distilled water [13].

Detection and quantification of CPV DNA was obtained by real-time PCR using a conventional TaqMan probe [13]. Briefly, the 25-μL reaction contained 12.5 μL of master mix (Bio-Rad Laboratories S.r.l., Milan, Italy), 600 nM of primers (5′-AAACAGGAATTAATATATATATATATTTA-3′) and CPV-Rev (5′-AAATTTGGAGCATTTTGGATAAATT-3′), 200 nM of probe CPV-Pb (5′-TGTCCTTAACTTGATATTACGTACC-3′) and 10 μL of standard or template DNA. For the standard-curve construction, ten-fold dilutions of a plasmid containing the nearly full-length CPV genome (kindly supplied by C.R. Parrish, Cornell University, Ithaca, NY, USA) were processed. All standard dilutions and unknown samples were tested in duplicate. The following thermal protocol was used: activation of iTaq DNA polymerase at 95 °C for 10 min and 40 cycles consisting of denaturation at 95 °C for 15 s, primer annealing at 52 °C for 30 s and extension at 60 °C for 1 min.

A panel of minor groove binder (MGB) probe assays able to predict the viral type [14,15] and to discriminate between vaccine and field strains of CPV [16,17] was used to confirm the viral strain detected in vaccinated dogs.

2.5. Serological investigations

Sera of dogs collected at dpv 0, 7, 14, 21 and 28 were submitted to an HI test using a standardized protocol [10]. The tests were performed at +4 °C in 96-well V-plates, using 10 hemagglutinating units of CPV-2 antigen and 0.8% pig erythrocytes. Two-fold dilutions in PBS of each serum sample, starting from 1:10, were tested. The HI titer was indicated as the highest serum dilution completely inhibiting viral hemagglutination.

2.6. Statistical analysis

The data were analyzed using the Prism 6 software (version 6.0d). All hypothesis tests were conducted at the 0.05 level of significance (two-sides). The areas under curve (AUC) for the viremia and fecal shedding of the vaccine viruses were calculated for each group and the statistical significance was evaluated using the Wilcoxon–Mann–Whitney test. Prior to analysis the AUC values were logarithmically transformed. HI antibody titers were also analyzed by the Wilcoxon test.

3. Results

3.1. CPV post-vaccinal viremia

By real-time PCR, dogs immunized with the CPV-2 strain displayed viremia for 19 mean days, from dpv 3 to 21, with mean viral titers peaking at dpv 10 (1.12 × 10^6 DNA copies 10 μL−1 of template). In dogs vaccinated with CPV-2b, viremia started at dpv 3 and stopped at dpv 24 (22 mean days), with maximal titers of 6.39 × 10^5 DNA copies 10 μL−1 of template being observed at dpv 7 (Fig. 1A).

Minor groove binder (MGB) probe assays developed to predict the antigenic type and discriminate between field and vaccine strains [14–17] confirmed the positivity for the vaccine strain (CPV-2 or CPV-2b) according to the vaccine group.

The mean values for the area under the curve of real time PCR results from EDTA–blood for the observation period were 4.55 × 10^6 and 2.37 × 10^6 for CPV-2 and CPV-2b vaccinated dogs, respectively (P < 0.001).

3.2. CPV post-vaccinal shedding

None fecal swab collected after vaccination tested positive by either in-clinic testing or HA. By real-time PCR, CPV-2 immunized pups shed the virus with the same pattern observed for viremia (19 mean days), although viral DNA loads detected in the feces were slightly lower than those observed in the blood. The highest DNA loads (mean of 3.80 × 10^5 DNA copies 10 μL−1 of template) were shed at dpv 7. Vaccinal CPV-2b shedding occurred for a shorter period (12 mean days, from dpv 3 to 14) but with greater viral load, which peaked at dpv 10 (mean titer of 1.12 × 10^6 DNA copies 10 μL−1 of template) (Fig. 1B). The vaccine strain shed through the
feces of CPV-2 or CPV-2b vaccinated dogs was confirmed by MGB probe testing [14–17].

The area under curve that resulted from the real-time PCR titers detected in fecal specimens during the entire observation period displayed mean values of $1.61 \times 10^6$ and $4.04 \times 10^6$ for pups immunized against CPV-2 and CPV-2b, respectively ($P < 0.05$).

### 3.3. CPV seroconversion

Fig. 1C illustrates the antibody patterns observed in the two vaccine groups. In dogs administered the CPV-2 vaccine, HI antibodies against CPV were first detected at dpv 14 (geometric mean titers of 8.10) and reached maximal values at dpv 28 (geometric mean titers of 10.10). In contrast, CPV-2b vaccinated dogs seroconverted already at dpv 7 (geometric mean titers of 1.97), although similar to the other vaccine group, maximal titers were reached at dpv 28 (geometric mean titers of 12.63). HI antibody titers induced by CPV-2b were generally higher in comparison to those raised against CPV-2 ($P < 0.001$).

### 4. Discussion

International guidelines for dog vaccination recommend the use of MLV vaccines to prevent infection by viruses included in the core vaccines, i.e. CPV, canine distemper virus and canine adenovirus [18]. MLV CPV strains are able to replicate in the bloodstream and intestinal mucosa of vaccinated dogs, despite the unnatural route of administration (intramuscular or subcutaneous instead of oronasal), causing viremia and fecal shedding [19,20]. In such a circumstance, the detection of CPV or its nucleic acid in the feces...
of vaccinated dogs could provide false-positive results, leading to a misdiagnosis of the disease probably caused by other enteric pathogens of dogs, i.e., canine coronavirus, canine distemper virus, reoviruses, rotaviruses, *Salmonella* spp., protozoa, parasites, etc. Moreover, there is the need to rule out vaccine-induced disease due to regaining of virulence of the vaccine virus. In a recent study [10], molecular testing of 29 fecal samples collected from dogs with diarrhea following CPV vaccination showed that in most cases those animals were infected by CPV field strains or other canine pathogens. However, 11 dogs were found to shed CPV vaccine strains in combination with field strains or other agents, whereas three samples tested positive for the vaccine strain without evidence of canine pathogens. To date, there are no molecular studies investigating the persistence of CPV vaccinal strains in the canine organism.

In order to assess the exact duration and extent of CPV vaccine-induced viremia and fecal shedding, 26 dogs were administered two commercial vaccines containing a CPV-2 or CPV-2b strain and monitored for 28 days after vaccination. By using real-time PCR, vaccine-induced viremia and fecal shedding occurred at higher titers for CPV-2b than for CPV-2. Interestingly, while viremia was observed for more days for CPV-2b (22 against 19 means days), the old-type vaccine strain was shed in the feces for a longer period (19 mean days) than the CPV-2b virus (12 mean days). Viral DNA loads detected by real-time PCR in the blood and feces of immunized dogs were generally much lower than those observed at least for the CPV variants causing natural or experimental infections [10,21,22]. In the feces, the field viruses can reach loads above 10^{12} DNA copies 10 μl⁻¹ of template, while vaginal strains were shed at maximal titers of 10^3–10^6 DNA copies 10 μl⁻¹ of template (mean values). As for the duration of the fecal shedding, it was surprising that CPV-2b, albeit shed at higher titers, was detected in the feces for a shorter period in comparison to the CPV-2 vaccinal strain. As expected, none vaccinated dogs displayed any clinical signs after vaccination. Moreover, the impact of concurrent infections on the MLV persistence was not investigated, thus requiring further studies.

Another striking finding was that both the in-clinic (ELISA-based) and laboratory (HA) assays that are routinely employed for CPV diagnosis gave negative results on the fecal samples from vaccinated dogs, even when the virus reached discrete titers that should be detected by the tests [12,23,11]. In-clinic testing and HA were proved to be poorly sensitive compared with nucleic acid-based assays, mainly due to sequestration of viral particles by gut antibodies especially during late infection [12,23,11]. In the present study, the maximal CPV DNA titers (more than 10^3 and 10^6 mean DNA copies 10 μl⁻¹ of template for CPV-2 and CPV-2b viruses) were detected as early as one week post-vaccination when serum HI antibody titers were still absent or very low (Fig. 1C). However, the kinetic of the mucosal antibody response was not investigated in vaccinated animals, so that the presence of high titers of gut antibodies, likely mucosal IgA, could not be ruled out. Our findings are in contrast with those of a recent study aiming to evaluate the feline panleukopenia virus (FPLV) vaccine-induced interference with feline parvovirus diagnostic testing in cats [24]. This study showed that some cats had in-clinic assay positive results after FPLV vaccination although all kits employed contained CPV antibodies.

In conclusion, the present study adds new insights into the CPV vaccine persistence in the organism and possible interference with diagnostic tests.

**Conflict of interest**

The authors declare no conflict of interest.

**Acknowledgements**

The authors thank Mr. Omar Machich and Dr. Valeria Bove for their help in sampling animals. This work was supported by grants from University of Bari (Contribution to PRIN 2008 “Epidemiologia molecolare dei parvovirus dei carnivori”).

**References**

[1] Decaro N, Buonavoglia C. An update on canine coronaviruses: viral evolution and pathobiology. Vet Microbiol 2008;132:221–34.
[2] Decaro N, Buonavoglia C. Canine coronavirus: not only an enteric pathogen. Vet Clin North Am Small Anim Pract 2011;38:799–814.
[3] Decaro N, Buonavoglia C. Canine parvovirus – a review of epidemiological and diagnostic aspects, with emphasis on type 2c. Vet Microbiol 2012;155:1–12.
[4] Decaro N, Desario C, Addie DD, Martella V, Vieira MJ, Elia G, et al. Molecular epidemiology of canine parvovirus, Europe. Emerg Infect Dis 2007;13:1222–4.
[5] Decaro N, Desario C, Parisi A, Martella V, Lorusso A, Miccolupo A, et al. Genetic analysis of canine parvovirus type 2c. Virology 2005;385:5–10.
[6] Decaro N, Desario C, Bili M, Mari V, Elia G, Cavalli A, et al. Western European epidemiological survey for parovirus and coronavirus infections in dogs. Vet J 2011;187:195–9.
[7] Decaro N, Desario C, Amorisco F, Losurdo M, Elia G, Parisi A, et al. Detection of a canine parvovirus type 2c with a non-coding mutation and its implications for molecular characterization. Vet J 2013;196:555–7.
[8] Hong C, Decaro N, Desario C, Tanner P, Pardo MC, Sanchez S, et al. Occurrence of canine parvovirus type 2c in the United States. J Vet Diagn Invest 2007;19:535–9.
[9] Decaro N, Desario C, Elia G, Campoilo M, Lorusso A, Mari V, et al. Occurrence of severe gastroenteritis in pups after canine parvovirus vaccine administration: a clinical and laboratory diagnostic dilemma. Vaccine 2007;25:1161–6.
[10] Decaro N, Campoilo M, Desario C, Elia G, Martella V, Lorusso E, et al. Maternally-derived antibodies in pups and protection from canine parovirus infection. Biologicals 2005;33:259–65.
[11] Decaro N, Desario C, Bili M, Lorusso E, Colaianni ML, Colau V, et al. Evaluation of an in-clinic assay for the diagnosis of canine parovirus. Vet J 2013;198:504–7.
[12] Desario C, Decaro N, Campoilo M, Cavalli A, Cirone F, Elia G, et al. Canine parovirus infection: which diagnostic test for virus. J Virol Methods 2005;121:179–85.
[13] Decaro N, Elia G, Martella V, Desario C, Campoilo M, Di Trani L, et al. A real-time PCR assay for rapid detection and quantitation of canine parvovirus type 2 DNA in the feces of dogs. Vet Microbiol 2005;105:19–28.
[14] Decaro N, Elia G, Campoilo M, Desario C, Lucente M, Bellaccco AL, et al. New approaches for the molecular characterization of canine parovirus type 2 strains. J Vet Med B Infect Dis Vet Public Health 2005;52:316–9.
[15] Decaro N, Elia G, Martella V, Campoilo M, Desario C, Camero M, et al. Characterisation of the canine parovirus type 2 variants using minor groove binder probe technology. J Virol Methods 2006;133:92–9.
[16] Decaro N, Elia G, Desario C, Roperto S, Martella V, Campoilo M, et al. A minor groove binder probe real-time PCR assay for discrimination between type 2-banded vaccines and field strains of canine parovirus. J Virol Methods 2006;136:65–70.
[17] Decaro N, Elia G, Martella V, Elia G, Desario C, Campoilo M, Buonavoglia D, et al. Diagnostic tools based on minor groove binder probe technology for rapid identification of vaccinal and field strains of canine parovirus type 2b. J Virol Methods 2006;138:10–6.
[18] Day MJ, Horzinek MC, Schultz RD, Vaccination Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA), Guidelines for the vaccination of dogs and cats. Compiled by the Vaccination Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA). J Small Anim Pract 2007;48:528–41.
[19] Buonavoglia C, Compagnucci M, Orfei Z. Dog response to plaque variant of canine parovirus. Zbl Vet Med B 1983;30:526.
[20] Carmichael LE, Pollock RV, Jaubert JC. Response of puppies to canine-origin parovirus vaccines. Mod Vet Pract 1984;65:99–102.
[21] Decaro N, Desario C, Campoilo M, Elia G, Martella V, Ricci D, et al. Clinical and virological findings in pups naturally infected by canine parovirus type 2 Glu-426 mutant. J Vet Diagn Invest 2005;17:133–8.
[22] Decaro N, Martella V, Elia G, Desario C, Campoilo M, Lorusso E, et al. Tissue distribution of the antigenic variants of canine parovirus type 2 in dogs. Vet Microbiol 2007;121:39–44.
[23] Decaro N, Desario C, Beall MJ, Cavalli A, Campoilo M, Dimarco AA, et al. Detection of canine parovirus type 2c by a commercially available in-house rapid test. Vet J 2010;184:373–5.
[24] Patterson EV, Reese MJ, Tucker SJ, Dubovi EJ, Crawford PC, Levy JK. Effect of vaccination on parovirus antigen testing in kittens. J Am Vet Med Assoc 2007;230:359–63.